Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04620187 · ClinicalTrials.gov registry record · Phase 2
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
A Phase 2 study of Salivary Gland Cancer and HER2 Gene Mutation, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 12
- Study locations
NCT04620187: Recruiting Phase 2 study of Salivary Gland Cancer and HER2 Gene Mutation, sponsored by Dana-Farber Cancer Institute.
NCT04620187 is a Phase 2 study of Salivary Gland Cancer and HER2 Gene Mutation that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 55 participants, roughly in line with the 59-participant average among 8 other Salivary Gland Cancer trials with a reported enrollment target. The trial reports 12 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04620187, a Phase 2 study of Salivary Gland Cancer and HER2 Gene Mutation, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 12
- Study locations
Study Summary
This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of study drug Ado-trastuzumab (T) emtansine (DM1) on cancer recurrence.
Primary Outcome
Kaplan-Meier method will be used to estimate 2 Year Disease-free survival (DFS) Rate
Conditions Studied
Interventions
- DRUG Standard of Care Chemotherapy
- DRUG Ado-trastuzumab (T) emtansine (T-DM1)
- RADIATION Standard of Care Radiotherapy
Study Locations (12)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Illinois
- University of Chicago - Chicago
Washington
- University of Washington Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2020-12-24 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
What NCT04620187 shows while recruiting
NCT04620187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, roughly in line with the 59-participant average among 8 other Salivary Gland Cancer trials with a reported enrollment target.
The record links to 2 conditions, with Salivary Gland Cancer appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care Chemotherapy is the first listed.
NCT04620187 lists 12 locations in 5 states (New York, New Jersey, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT04620187 about?
NCT04620187 is a clinical study titled "Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas". This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of study drug Ado-trastuz...
What is the current status of trial NCT04620187?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2020-12-24. Estimated completion is 2029-02-01.
What conditions does trial NCT04620187 study?
This clinical trial studies the following conditions: Salivary Gland Cancer, HER2 Gene Mutation.
What interventions are being tested in trial NCT04620187?
The interventions under investigation include: Standard of Care Chemotherapy (DRUG), Ado-trastuzumab (T) emtansine (T-DM1) (DRUG), Standard of Care Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT04620187?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04620187 being conducted?
This trial has 12 study locations across Illinois, Massachusetts, New Jersey, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Salivary Gland Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04620187's enrollment target sits among peer trials
55 3rd of 8 higher than 6 of 8 other Salivary Gland Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Salivary Gland Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
-
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Amivantamab in Adenoid Cystic Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI